Campos Joana F, Besson Thierry, Berteina-Raboin Sabine
Institut de Chimie Organique et Analytique (ICOA), Université d'Orléans CNRS, ICOA UMR 7311, BP 6759, Rue de Chartres, CEDEX 2, 45067 Orléans, France.
Université de Rouen-Normandie (UNIROUEN), INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France.
Pharmaceuticals (Basel). 2022 Mar 14;15(3):352. doi: 10.3390/ph15030352.
The objective of this review is to list the structures composed of a pyridopyrimidine moiety which have shown a therapeutic interest or have already been approved for use as therapeutics. We consider all the synthetic protocols to prepare these pyridopyrimidine derivatives. The review is organized into four sections, successively pyrido[2,3-]pyrimidines, pyrido[3,4-]pyrimidines, pyrido[4,3-]pyrimidines and pyrido[3,2-]pyrimidines. For each compound we present the biological activity and the synthetic route reported. To produce this manuscript, the bibliographic research was done using Reaxys and Scifinder for each kind of pyridopyrimidine.
本综述的目的是列出由吡啶并嘧啶部分组成的、已显示出治疗价值或已被批准用作治疗药物的结构。我们考虑了制备这些吡啶并嘧啶衍生物的所有合成方案。本综述分为四个部分,依次为吡啶并[2,3-]嘧啶、吡啶并[3,4-]嘧啶、吡啶并[4,3-]嘧啶和吡啶并[3,2-]嘧啶。对于每种化合物,我们介绍了其生物活性和所报道的合成路线。为撰写本手稿,针对每种吡啶并嘧啶,利用Reaxys和Scifinder进行了文献调研。